Today: 9 June 2026
Browse Category

Health News 25 January 2026 - 2 June 2026

Boston Scientific Hits Two-Year Low After Watchman Device Warning

Boston Scientific Hits Two-Year Low After Watchman Device Warning

Boston Scientific shares fell about 10% Wednesday after CEO Mike Mahoney warned of weaker demand for its Watchman heart implant. The stock hit $50.60, its lowest in over two years. Mahoney said Watchman sales likely won’t grow from the first to third quarter, citing a shift to combined procedures. The company maintained its full-year organic revenue growth forecast of 6.5% to 8%.
27 May 2026
··
Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics Stock Surges on Ebola Assay News — The Fine Print Is Big

Co-Diagnostics shares surged 51% Tuesday after the company announced completion of an assay strategy for the Bundibugyo Ebola virus, though the test is not yet for sale and awaits regulatory approval. Trading volume topped 94 million shares. The company reported $8.23 million in cash at March 31 and a quarterly net loss of $9.14 million, raising concerns about its financial stability.
19 May 2026
···
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
14 May 2026
····
SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Stock Jumps After AML Trial Moves Two Events From Final Readout

SELLAS Life Sciences said its pivotal REGAL leukemia trial has recorded 78 of 80 events needed for final analysis, triggering a rise in after-hours trading. The company reported a first-quarter net loss of $8.4 million but ended March with $107.1 million in cash. Research and development spending increased to $5.1 million. SELLAS expects its cash to fund operations for at least 12 months.
13 May 2026
···
Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna Stock Gets Fresh Hantavirus Jolt As Cruise-Ship Outbreak Widens

Moderna’s early-stage hantavirus vaccine research drew renewed attention after a deadly Andes virus outbreak on the MV Hondius cruise ship, with six confirmed cases and three deaths reported. Moderna shares closed up nearly 12% Friday. WHO and ECDC rated the broader public risk as low, but recommended a 42-day quarantine for passengers. No approved vaccine or treatment for Andes virus exists, according to the CDC.
11 May 2026
··
Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma Stock Jumps As Biotech Targets Hantavirus After Cruise Ship Deaths

Traws Pharma said it will advance clinical candidates for hantavirus after a cruise-ship outbreak killed three people, with no lead drug named yet. WHO confirmed five hantavirus cases on the MV Hondius, three fatal, and said person-to-person spread is limited. Traws shares jumped 21.8% after the announcement. The company has no approved products and recently raised $10 million in private funding.
8 May 2026
···
Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s New Weight-Loss Pill Has an Early Problem: Novo’s Head Start

Eli Lilly’s new oral weight-loss drug Foundayo was prescribed 3,707 times in its second week on the U.S. market, well below Novo Nordisk’s oral Wegovy, which saw 18,410 prescriptions in the same period after launch. Lilly shares fell about 4% following the data, while Novo Nordisk’s U.S. shares rose nearly 6%. Foundayo was approved by the FDA on April 1 and began shipping April 6.
24 April 2026
···
Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health Stock Jumps as FDA Reconsiders Peptide Restrictions

Hims & Hers Health shares rose to $26.65 Thursday after the FDA said it would reconsider restrictions on several peptides, removing 12 from a high-risk list and scheduling a July review of seven more. The move follows Hims’ March decision to stop advertising compounded GLP-1 drugs and expand branded offerings through Novo Nordisk. The company acquired a California peptide facility last year to bolster supply.
16 April 2026
···
Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly Stock Wobbles After Retatrutide Trial Win as Pricing Fears Bite

Eli Lilly said its obesity and diabetes drug candidate retatrutide met main goals in a late-stage trial, cutting A1C by up to 2% and body weight by 16.8%. Shares traded at $918.05, down 1.3% after an HSBC downgrade and concerns over U.S. price cuts. Side effects included nausea and vomiting, with a 5.1% discontinuation rate at the highest dose. Detailed results will be presented in June.
19 March 2026
···
AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie Obesity Drug ABBV-295 Hits Up to 9.8% Weight Loss in Early Trial

AbbVie said its experimental obesity drug ABBV-295 led to up to 9.79% weight loss in adults over 12 weeks in a 76-patient phase 1 trial, with no serious adverse events reported. Weekly and less-frequent dosing schedules showed similar results, while placebo groups saw little change. The study population was mostly male with a mean BMI under 30. ABBV-295 is not approved and remains in early-stage testing.
10 March 2026
····
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure stock jumps in premarket after FDA clears Optune Pax for pancreatic cancer

NovoCure shares jumped 23% to $12.91 in U.S. premarket trading Thursday after the FDA approved its Optune Pax device for locally advanced pancreatic cancer. The company said this is the first new FDA-approved treatment for the disease in nearly 30 years. In a Phase 3 trial, median overall survival was 16.2 months with Optune Pax plus chemotherapy, compared to 14.2 months with chemotherapy alone.
12 February 2026
·
Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk Class B stock: what to watch after Hims pulls $49 Wegovy pill copy

Novo Nordisk B shares rose 5.29% to 295.50 Danish crowns Friday after Hims & Hers said it would stop selling a $49 compounded version of Novo’s Wegovy pill. The rebound followed a steep two-day drop and came as the FDA pledged action against mass-marketed copycats. The stock remains down about 20% over five sessions. Investors remain uncertain about Novo’s patent protections and future pricing power.
8 February 2026
···
ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio stock tumbles after glioblastoma update; what to watch before Monday

ImmunityBio shares fell 12.1% to $6.45 Friday after the company previewed new data from its Phase 2 glioblastoma trial, with full results due Jan. 31. The stock traded heavily between $7.88 and $6.43. Median overall survival in the study was “not yet reached” as of Jan. 22, with 19 of 23 patients alive. Investors are watching for more details on durability, safety, and trial design.
25 January 2026
·····
1 2 3 4

Stock Market Today

  • Dollar General's Q1 Same-Store Sales Signal Growth Potential
    June 9, 2026, 1:55 PM EDT. Dollar General reported a 2% increase in first-quarter same-store sales, driven primarily by a 1.4% rise in customer traffic and 0.5% increase in average transaction value. This traffic-led growth suggests more frequent customer visits rather than price hikes. All merchandise categories posted positive comparable sales for a fifth consecutive quarter, with non-consumables outperforming consumables. Despite early quarter weather disruptions, the company saw consistent sales through March and early May, reaffirming its 2026 forecast of 2.2%-2.7% same-store sales growth. Dollar General's valuation appears modest, trading with a forward price-to-earnings ratio of 14.19 against an industry median of 31.30, though shares have fallen nearly 27% over three months. The retailer's value proposition continues to attract repeat visits amid competition from Walmart and Target, which posted higher comparable sales growth in recent quarters.

Latest articles

AHMA Shares Jump Over 100% With Little News Out

AHMA Shares Jump Over 100% With Little News Out

9 June 2026
Ambitions Enterprise Management Co. L.L.C shares soared 185% to $3.08 on Nasdaq with over 60 million shares traded, despite no new company news since April 30; the surge outpaced travel peers and left the price below its $4 IPO, with the company warning in its annual report of potential volatility, competition, seasonal risks, and a $5 million capital need.
Rigetti Drops 14% With Quantum Names Hit in Tech Selloff

Rigetti Drops 14% With Quantum Names Hit in Tech Selloff

9 June 2026
Rigetti shares plunged 14.4% to $18.64, erasing gains from bullish Bernstein commentary, as investors dumped high-growth tech stocks sector-wide despite analyst optimism on quantum computing’s future; the drop followed a director’s proposed stock sale and comes as Rigetti awaits finalization of a potential $100 million federal award.
Archer Aviation Drops After Cathie Wood Selloff; What Traders Are Tracking

Archer Aviation Drops After Cathie Wood Selloff; What Traders Are Tracking

9 June 2026
Archer Aviation plunged 9.1% to $5.21 after ARK Invest dumped over 2.2 million shares worth $12.7 million, intensifying pressure as investors fled speculative growth stocks; with FAA certification still pending and heavy cash burn, Archer’s stock remains vulnerable to further selloffs if milestones slip.
Aurora Shares Fall as Uber Pulls Back, Tech Stocks Struggle

Aurora Shares Fall as Uber Pulls Back, Tech Stocks Struggle

9 June 2026
Aurora shares dropped 3.5% to $6.04 as tech and autonomous-driving stocks slid, with Uber’s recent block sale of 67.5 million shares at $7.10 still weighing on sentiment; Aurora reported a Q1 net loss of $223 million on $1 million revenue, expects continued losses, and may need to raise more capital to support its commercial ramp.
Go toTop